Each SOP document is a unit of risk,” said Paul Mathews, director of product management at CSC. “When the volume rises, there ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

Tarrytown-based Regeneron Pharmaceuticals is planning to spend $2 billion to expand and upgrade its presence in Saratoga Springs in Upstate New York. The expansion is expected to create an estimated 1 ...

FDA approved EYLEA HD for macular edema post-RVO with up to 8-week dosing after initial monthly doses. Phase 3 QUASAR trial showed non-inferior visual acuity gains with EYLEA HD compared to EYLEA.

After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns. Regeneron’s high-dose ...

Every upgrade to Eylea HD’s label helps as Regeneron fights for prescriptions in an eye disease market it once dominated with original Eylea. The approval for retinal vein occlusion may open up as ...

Regeneron Pharmaceuticals (REGN) has received approval from the European Commission for Libtayo (cemiplimab), to be used as an adjuvant treatment for adults with cutaneous squamous cell carcinoma ...

Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...

23andMe’s bankruptcy judge preliminarily approved a settlement with arbitration claimants as part of a broader effort to provide up to $62 million to resolve thousands of data breach claims. Judge ...

Fallen DNA testing firm 23andMe increased a settlement offer to $9 million for thousands of arbitration claimants who pursued claims tied to a 2023 data breach. A revised settlement aims to resolve ...